These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 33278029)

  • 1. Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review.
    Guirguis E; Grace Y; Bolson A; DellaVecchia MJ; Ruble M
    Pharmacotherapy; 2021 Mar; 41(3):315-328. PubMed ID: 33278029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of drugs for nonalcoholic steatohepatitis.
    Shen B; Lu LG
    J Dig Dis; 2021 Feb; 22(2):72-82. PubMed ID: 33385317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.
    Polyzos SA; Kang ES; Boutari C; Rhee EJ; Mantzoros CS
    Metabolism; 2020 Oct; 111S():154203. PubMed ID: 32151660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
    Ratziu V; Sanyal AJ; Loomba R; Rinella M; Harrison S; Anstee QM; Goodman Z; Bedossa P; MacConell L; Shringarpure R; Shah A; Younossi Z
    Contemp Clin Trials; 2019 Sep; 84():105803. PubMed ID: 31260793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future pharmacological therapies for NAFLD/NASH.
    Sumida Y; Yoneda M
    J Gastroenterol; 2018 Mar; 53(3):362-376. PubMed ID: 29247356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Pharmacotherapy Options for NASH.
    Ratziu V
    Dig Dis Sci; 2016 May; 61(5):1398-405. PubMed ID: 27003143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Gawrieh S; Chalasani N
    Clin Liver Dis; 2018 Feb; 22(1):189-199. PubMed ID: 29128056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis.
    Sumida Y; Okanoue T; Nakajima A;
    Hepatol Res; 2019 Nov; 49(11):1256-1262. PubMed ID: 31495973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming.
    Jeong SW
    Diabetes Metab J; 2020 Oct; 44(5):640-657. PubMed ID: 33115209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
    Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
    Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
    Sanyal AJ; Ratziu V; Loomba R; Anstee QM; Kowdley KV; Rinella ME; Sheikh MY; Trotter JF; Knapple W; Lawitz EJ; Abdelmalek MF; Newsome PN; Boursier J; Mathurin P; Dufour JF; Berrey MM; Shiff SJ; Sawhney S; Capozza T; Leyva R; Harrison SA; Younossi ZM
    J Hepatol; 2023 Nov; 79(5):1110-1120. PubMed ID: 37517454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need.
    Guaraldi G; Maurice JB; Marzolini C; Monteith K; Milic J; Tsochatzis E; Bhagani S; Morse CG; Price JC; Ingiliz P; Lemoine M; Sebastiani G;
    Hepatology; 2020 May; 71(5):1831-1844. PubMed ID: 32052857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?].
    Huber Y; Galle PR; Schattenberg JM
    Z Gastroenterol; 2020 Jan; 58(1):68-73. PubMed ID: 31931543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
    Zhao J; Li B; Zhang K; Zhu Z
    Medicine (Baltimore); 2024 Feb; 103(7):e37271. PubMed ID: 38363900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
    Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
    [No Abstract]   [Full Text] [Related]  

  • 18. Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials.
    Connolly JJ; Ooka K; Lim JK
    J Clin Transl Hepatol; 2018 Sep; 6(3):264-275. PubMed ID: 30271738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials.
    Aggarwal P; Noureddin M; Harrison S; Jeannin S; Alkhouri N
    Expert Opin Investig Drugs; 2022 Feb; 31(2):163-172. PubMed ID: 35060815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.